Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • Log out
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Experimental Therapeutics

Sulindac Sulfone Inhibits Azoxymethane-induced Colon Carcinogenesis in Rats without Reducing Prostaglandin Levels

Gary A. Piazza, David S. Alberts, Lee J. Hixson, Nancy Shipp Paranka, Han Li, Tyler Finn, Cheryl Bogert, Jose M. Guillen, Klaus Brendel, Paul H. Gross, Gerhard Sperl, Justine Ritchie, Randall W. Burt, Lansing Ellsworth, Dennis J. Ahnen and Rifat Pamukcu
Gary A. Piazza
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David S. Alberts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lee J. Hixson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nancy Shipp Paranka
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Han Li
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tyler Finn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cheryl Bogert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jose M. Guillen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Klaus Brendel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul H. Gross
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerhard Sperl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Justine Ritchie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Randall W. Burt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lansing Ellsworth
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dennis J. Ahnen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rifat Pamukcu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published July 1997
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs), such as sulindac, have cancer chemopreventive properties by a mechanism that has been suggested to involve cyclooxygenase inhibition and reduction of prostaglandin (PGE2) levels in the target tissue. To test this hypothesis, we studied the effect of dietary sulindac sulfone (500–2000 ppm), a metabolite of sulindac reported to lack cyclooxygenase inhibitory activity, on tumor formation and PGE2 levels in the azoxymethane model of colon carcinogenesis. Rats treated with sulindac at 400 ppm and piroxicam at 150 ppm were used as positive controls. Rats received two s.c. injections of azoxymethane (15 mg/kg) for 2 weeks and were fed either experimental or control diets until necropsy. After 31 weeks of sulfone treatment, a dose-related increase in sulfone levels in both serum and cecal contents was measured; there was no evidence of metabolic conversion to sulindac or other metabolites. Rats treated with sulfone at 1000 and 2000 ppm, sulindac, and piroxicam had significantly fewer colonic adenomas and carcinomas compared with rats fed control diet as measured by tumor incidence, multiplicity, and tumor burden. Sulfone-treated rats also showed a dose-response relationship for inhibiting all tumor parameters. Colons from rats treated with sulindac or piroxicam contained PGE2 levels that ranged from approximately 16–49% of control levels. PGE2 levels in rats treated with sulfone up to 2000 ppm ranged from 78–118% of control levels. Moreover, the effects of sulindac sulfone on various enzymes responsible for regulating prostaglandin levels were evaluated. No significant inhibitory effects were observed for cyclooxygenase, lipoxygenase, or phospholipase A2. These results suggest that reduction of prostaglandin levels in the target tissue may not be necessary for the chemopreventive properties of sulindac.

Footnotes

  • ↵1 Supported by a grant from Cell Pathways, Inc., Aurora, Colorado and by the Veterans Affairs Merit Review Grant 1312.

  • ↵2 To whom requests for reprints should be addressed, at Cell Pathways, Inc., 1300 South Potomac Street, Suite 110, Aurora, CO 80012.

  • Received September 25, 1996.
  • Accepted May 14, 1997.
  • ©1997 American Association for Cancer Research.
PreviousNext
Back to top
July 1997
Volume 57, Issue 14
  • Table of Contents
  • Table of Contents (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Sulindac Sulfone Inhibits Azoxymethane-induced Colon Carcinogenesis in Rats without Reducing Prostaglandin Levels
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Sulindac Sulfone Inhibits Azoxymethane-induced Colon Carcinogenesis in Rats without Reducing Prostaglandin Levels
Gary A. Piazza, David S. Alberts, Lee J. Hixson, Nancy Shipp Paranka, Han Li, Tyler Finn, Cheryl Bogert, Jose M. Guillen, Klaus Brendel, Paul H. Gross, Gerhard Sperl, Justine Ritchie, Randall W. Burt, Lansing Ellsworth, Dennis J. Ahnen and Rifat Pamukcu
Cancer Res July 15 1997 (57) (14) 2909-2915;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Sulindac Sulfone Inhibits Azoxymethane-induced Colon Carcinogenesis in Rats without Reducing Prostaglandin Levels
Gary A. Piazza, David S. Alberts, Lee J. Hixson, Nancy Shipp Paranka, Han Li, Tyler Finn, Cheryl Bogert, Jose M. Guillen, Klaus Brendel, Paul H. Gross, Gerhard Sperl, Justine Ritchie, Randall W. Burt, Lansing Ellsworth, Dennis J. Ahnen and Rifat Pamukcu
Cancer Res July 15 1997 (57) (14) 2909-2915;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Experimental Therapeutics

  • Phosphatidylinositol 3′-Kinase Is Required for Growth of Mast Cells Expressing the Kit Catalytic Domain Mutant
  • Antitumor Effect by Interleukin-11 Receptor α-Locus Chemokine/CCL27, Introduced into Tumor Cells through a Recombinant Adenovirus Vector
  • Mammary Carcinoma Suppression by Cellular Retinoic Acid Binding Protein-II
Show more Experimental Therapeutics

Articles

  • Genetic Control of Programmed Cell Death in the Nematode Caenorhabditis elegans
  • The Prizes
  • Role of TCL1 and ALL1 in Human Leukemias and Development
Show more Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement